Showing 1,141 - 1,160 results of 27,262 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 50 ((ns decrease) OR (we decrease)) ))', query time: 1.01s Refine Results
  1. 1141
  2. 1142
  3. 1143
  4. 1144
  5. 1145
  6. 1146
  7. 1147
  8. 1148

    Passenger mutations accurately classify human tumors by Marina Salvadores (6589187)

    Published 2019
    “…In particular, introducing the RMD features into a combined classification model increased the fraction of diagnosed patients by 50 percentage points (at 20% FDR). …”
  9. 1149

    Discovery of Novel Substituted <i>N</i>‑(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors by Jimin Xu (2208961)

    Published 2020
    “…Notably, among these derivatives, compound <b>15</b> showed improved anti-HAdV activity (IC<sub>50</sub> = 0.27 μM), significantly decreased cytotoxicity (CC<sub>50</sub> = 156.8 μM), and low <i>in vivo</i> toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further <i>in vivo</i> efficacy studies for the treatment of HAdV infections.…”
  10. 1150

    CREB Targets Define the Gene Expression Signature of Malignancies Having Reduced Levels of the Tumor Suppressor Tristetraprolin by Mohammad Fallahi (200679)

    Published 2014
    “…These analyses defined a signature of 50 genes differentially regulated between high and low <i>TTP</i>-expressing tumors. …”
  11. 1151
  12. 1152
  13. 1153
  14. 1154

    Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2 by Marta E. Capala (652765)

    Published 2015
    “…Downregulation of SAM50 also impaired the proliferation and replating capacity of BCR-ABL-expressing cells, again associated with a decreased mitochondrial membrane potential. …”
  15. 1155

    Discovery of a Potent SARM1 Base-Exchange Inhibitor with In Vivo Efficacy by Maude Giroud (2017114)

    Published 2025
    “…When tested in vivo, compound <b>7</b> showed efficacy after oral dosing in a mouse model of peripheral nerve injury by decreasing plasma neurofilament light (NfL) levels at 50 mg/kg compared with vehicle-treated control mice, holding promise for the treatment of neurodegenerative and neurological disorders.…”
  16. 1156
  17. 1157

    Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial by Michel Mandro (2637532)

    Published 2020
    “…<div><p>Introduction</p><p>Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a randomized clinical trial to assess whether ivermectin treatment decreases seizure frequency.…”
  18. 1158
  19. 1159
  20. 1160